Cited by 59Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Association of cerebrospinal fluid α‐synuclein with total and phospho‐tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers

Open access
Vergallo, Andrea, Bun, René‐Sosata, Toschi, Nicola, Baldacci, Filippo, Zetterberg, Henrik, Blennow, Kaj, Cavedo, Enrica, Lamari, Foudil +8 more·2018·Alzheimer's & Dementia

Abstract

Introduction: Several neurodegenerative brain proteinopathies, including Alzheimer's disease (AD), are associated with cerebral deposition of insoluble aggregates of α‐synuclein. Previous studies reported a trend toward increased cerebrospinal fluid (CSF) α‐synuclein (α‐syn) concentrations in AD compared with other neurodegenerative diseases and healthy controls. Methods: The pathophysiological role of CSF α‐syn in asymptomatic subjects at risk of AD has not been explored. We performed a large‐scale cross‐sectional observational monocentric study of preclinical individuals at risk for AD (INSIGHT‐preAD). Results: We found a positive association between CSF α‐syn concentrations and brain β‐amyloid deposition measures as mean cortical standard uptake value ratios. We demonstrate positive correlations between CSF α‐syn and both CSF t‐tau and p‐tau 181 concentrations. Discussion: Animal models presented evidence, indicating that α‐syn may synergistically and directly induce fibrillization of both tau and β‐amyloid. Our data indicate an association of CSF α‐syn with AD‐related pathophysiological mechanisms, during the preclinical phase of the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.06.3053

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In mild cognitive impairment patients who progressed to Alzheimer's disease over 24 months, there is a dose-response relationship between the APOEε4 allele and cerebrospinal fluid αSyn levels, with APOEε4 homozygous carriers exhibiting the highest cerebrospinal fluid αSyn concentrations.

    “we documented a dose-response relationship between the APOEε4 allele and CSF αSyn levels where APOEε4 homozygous carriers exhibited the highest CSF αSyn concentrations [26].”

    From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [26]

  • A relationship between brain amyloid-β load and cerebrospinal fluid αSyn levels was previously proposed by Vergallo and co-authors in cognitively normal individuals with subjective memory complaints stratified by Alzheimer's disease biomarkers.

    “A relationship between brain Aβ load and CSF αSyn levels was previously proposed by Vergallo and co-authors who examined cognitively normal individuals with subjective memory complaints stratified by AD biomarkers [26].”

    From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [26]

  • CSF αSyn is positively correlated with CSF t-tau and p-tau.

    “CSF αSyn positively correlated to CSF t-tau and p-tau”

    From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as Vergallo et al. 2018 [26]

  • Increased CSF αSyn is associated with increased brain Aβ deposition.

    “Increased CSF αSyn associated with increased brain Aβ deposition”

    From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as Vergallo et al. 2018 [26]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 37 · Cited by 59

Authors
Vergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., Floris, R., Garaci, F., Lista, S., Hampel, H., INSIGHT‐preAD study group, & (APMI), F. T. L. P. M. I.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • University of Rome Tor Vergata (IT)
  • University of Pisa (IT)
  • Sahlgrenska University Hospital (SE)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Vergallo, Andrea
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2018-07-25
Volume
14
Issue
12
Pages
1623-1631
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2883052156
Cited by
59
References
37
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 14 · 2018: 3
FWCI
6.88
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc-nd)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Funders
  • Rotary Foundation (GG1758249)
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
tau phosphorylation
MeSH terms
Aged, Alzheimer Disease, Amyloid, Brain, Cognition, Cross-Sectional Studies, Female, Humans, Male, Memory Disorders, Cohort Studies, Biomarkers, tau Proteins, Positron-Emission Tomography, alpha-Synuclein, Apolipoprotein E4, Diagnostic Self Evaluation, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review